Poltreg Inkomsten in het verleden
We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf
Verleden criteriumcontroles 0/6
Poltreg's earnings have been declining at an average annual rate of -64.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 14% per year.
Belangrijke informatie
-64.4%
Groei van de winst
-52.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 56.3% |
| Inkomstengroei | 14.0% |
| Rendement op eigen vermogen | -18.6% |
| Nettomarge | -1,738.6% |
| Volgende winstupdate | 21 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Will Poltreg (WSE:PTG) Spend Its Cash Wisely?
Sep 10
Is Poltreg (WSE:PTG) In A Good Position To Invest In Growth?
Mar 13Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 21We Think Poltreg (WSE:PTG) Can Afford To Drive Business Growth
Oct 05Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 16Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans
Feb 24Opbrengsten en kosten
Hoe Poltreg geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -16 | 15 | 0 |
| 31 Dec 23 | 1 | -14 | 16 | 0 |
| 30 Sep 23 | 1 | -10 | 15 | 0 |
| 30 Jun 23 | 1 | -5 | 12 | 0 |
| 31 Mar 23 | 1 | -2 | 9 | 0 |
| 31 Dec 22 | 1 | -2 | 7 | 0 |
| 30 Sep 22 | 1 | -4 | 8 | 0 |
| 30 Jun 22 | 1 | -4 | 8 | 0 |
| 31 Mar 22 | 1 | -4 | 7 | 0 |
| 31 Dec 21 | 1 | -4 | 6 | 0 |
| 30 Sep 21 | 1 | -2 | 4 | 0 |
| 30 Jun 21 | 1 | -1 | 3 | 0 |
| 31 Mar 21 | 1 | -1 | 3 | 0 |
| 31 Dec 20 | 1 | -1 | 3 | 0 |
| 31 Dec 19 | 1 | -1 | 2 | 0 |
Kwaliteitswinsten: PTG is currently unprofitable.
Groeiende winstmarge: PTG is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PTG is unprofitable, and losses have increased over the past 5 years at a rate of 64.4% per year.
Versnelling van de groei: Unable to compare PTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: PTG has a negative Return on Equity (-18.57%), as it is currently unprofitable.